Oncotarget

Research Papers:

RhoGDI deficiency induces constitutive activation of Rho GTPases and COX-2 pathways in association with breast cancer progression

William P. Bozza _, Yaqin Zhang, Kory Hallett, Leslie A. Rivera Rosado and Baolin Zhang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:32723-32736. https://doi.org/10.18632/oncotarget.5416

Metrics: PDF 1253 views  |   HTML 1759 views  |   ?  


Abstract

William P. Bozza1, Yaqin Zhang1, Kory Hallett1, Leslie A. Rivera Rosado1,2, Baolin Zhang1

1Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA

2United States Public Health Service Commissioned Corps, Rockville, MD 20852, USA

Correspondence to:

Baolin Zhang, e-mail: Baolin.zhang@fda.hhs.gov

Keywords: RhoGDI, breast cancer, tumor growth, Rho GTPases, COX-2 activation

Received: June 01, 2015     Accepted: September 15, 2015     Published: September 25, 2015

ABSTRACT

Rho GDP Dissociation Inhibitor (RhoGDI) is a key regulator of Rho GTPases. Here we report that loss of RhoGDI significantly accelerated xenograft tumor growth of MDA-MB-231 cells in animal models. At the molecular level, RhoGDI depletion resulted in constitutive activation of Rho GTPases, including RhoA, Cdc42, and Rac1. This was accompanied by Rho GTPase translocation from the cytosol to membrane compartments. Notably, COX-2 protein levels, mRNA expression, and biological activity were markedly increased in RhoGDI-deficient cells. The upregulated expression of COX-2 was directly associated with increased Rho GTPase activity. Further, we assessed the expression level of RhoGDI protein in breast tumor specimens (n = 165) by immunohistochemistry. We found that RhoGDI expression is higher in the early stages of breast cancer followed by a significant decrease in malignant tumors and metastatic lesions (p < 0.01). These data suggest that downregulation of RhoGDI could be a critical mechanism of breast tumor development, which may involve the hyperactivation of Rho GTPases and upregulation of COX-2 activity. Additional studies are warranted to evaluate the therapeutic potential of inhibiting Rho GTPases and COX-2 for treating breast cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5416